Microbix Biosystems Inc
MBX
Company Profile
Business description
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
Contact
265 Watline Avenue
MississaugaONL4Z 1P3
CANT: +1 905 234-1624
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
130
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,347.20 | 0.00 | 0.00% |
| DAX 40 | 25,420.66 | 15.32 | 0.06% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 26,947.64 | 99.17 | 0.37% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,121.57 | 17.19 | -0.42% |